Multiplexed single-cell RNA-seq via transient barcoding for simultaneous expression profiling of various drug perturbations
The development of high-throughput single-cell RNA sequencing (scRNA-seq) has enabled
access to information about gene expression in individual cells and insights into new …
access to information about gene expression in individual cells and insights into new …
Personalized therapy design for liquid tumors via optimal control theory
One of the key challenges in current cancer research is the development of reliable methods
for the definition of personalized therapeutic strategies, based on increasingly available …
for the definition of personalized therapeutic strategies, based on increasingly available …
An investigation into the role of ULK1 in regulating chronic myeloid leukaemia stem and progenitor cell differentiation and sensitivity to tyrosine kinase inhibitors
A Ianniciello - 2019 - theses.gla.ac.uk
Chronic Myeloid leukaemia (CML) is a stem cell driven disease, and a paradigm for cancer
stem cell biology and targeted therapy. The BCR-ABL oncoprotein is expressed in the most …
stem cell biology and targeted therapy. The BCR-ABL oncoprotein is expressed in the most …
[PDF][PDF] STUDIUM GENETICKÝCH ZMĚN U PACIENTŮ S CHRONICKOU MYELOIDNÍ LEUKÉMIÍ
M ZEJDOVÁ - is.muni.cz
Chronická myeloidní leukémie (CML) patří díky léčbě tyrozin kinázovými inhibitory (TKI)
mezi dobře zvladatelné malignity. Pacienti však často podstupují nákladnou doživotní léčbu …
mezi dobře zvladatelné malignity. Pacienti však často podstupují nákladnou doživotní léčbu …
Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia
BCS Leow - 2019 - digital.library.adelaide.edu.au
Resistance to therapeutic drugs is detrimental to treatment efficacy in chronic myeloid
leukaemia (CML). CML is driven by the constitutive activity of the tyrosine kinase, Bcr-Abl …
leukaemia (CML). CML is driven by the constitutive activity of the tyrosine kinase, Bcr-Abl …